Invitrogen™ Divozilimab Recombinant Monoclonal Antibody

Description

For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.

Divozilimab, an anti-CD20 monoclonal antibody, is developed for the treatment of multiple sclerosis, specifically relapsing-remitting multiple sclerosis (RRMS) and secondary progressive MS (SPMS) with relapses. The CD20 gene, also known as MS4A1, encodes a B cell-specific membrane-bound protein that plays a crucial role in B cell development and function. Located on chromosome 11q12 in humans, the MS4A1 gene spans 16 kb and includes eight exons. CD20 is a part of the membrane-spanning 4-domain family, subfamily A (MS4A), which encompasses 18 tetraspan proteins. The prominent CD20 mRNA variant is 2.8 kb long, although other shorter variants exist. This phosphoprotein, approximately 33-37 kDa, is expressed on the surface of almost all normal and malignant B cells, making it an ideal target for therapeutic antibodies like rituximab. CD20 is known to interact with several proteins such as CD40, MHCII, and CD81, playing a role in B cell receptor signaling and other immune processes. Despite its widespread clinical use in B cell depletion therapies, the precise biological function of CD20 remains partly unresolved.